Xiaowen Tang

ORCID: 0000-0003-1766-7891
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Acute Myeloid Leukemia Research
  • Hematopoietic Stem Cell Transplantation
  • CAR-T cell therapy research
  • Acute Lymphoblastic Leukemia research
  • Chronic Myeloid Leukemia Treatments
  • Immune Cell Function and Interaction
  • Chronic Lymphocytic Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Histone Deacetylase Inhibitors Research
  • Mitochondrial Function and Pathology
  • Mesenchymal stem cell research
  • Hematological disorders and diagnostics
  • Multiple Myeloma Research and Treatments
  • Lymphoma Diagnosis and Treatment
  • RNA and protein synthesis mechanisms
  • Virus-based gene therapy research
  • Protein Degradation and Inhibitors
  • Polyomavirus and related diseases
  • Retinoids in leukemia and cellular processes
  • Neutropenia and Cancer Infections
  • Cytomegalovirus and herpesvirus research
  • RNA modifications and cancer
  • T-cell and B-cell Immunology
  • Hearing, Cochlea, Tinnitus, Genetics
  • Advancements in Semiconductor Devices and Circuit Design

Soochow University
2016-2025

First Affiliated Hospital of Soochow University
2016-2025

National Clinical Research
2020-2025

Qingdao University
2022-2025

Shanghai Traditional Chinese Medicine Hospital
2025

Beijing Dao Pei Hospital
2024

Wuyi University
2024

Tianjin Medical University General Hospital
2024

Pudong Medical Center
2021-2024

Fudan University
2021-2024

Abstract The consensus recommendations in 2018 from Chinese Society of Hematology (CSH) on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation (allo-HSCT) facilitated the standardization clinical practices allo-HSCT China progressive integration with world. There have been new developments since initial publication. To integrate recent further improve consensus, a panel experts CSH recently updated recommendations, which are...

10.1186/s13045-021-01159-2 article EN cc-by Journal of Hematology & Oncology 2021-09-15

Background: Nanobodies, named as VHHs (variable domain of heavy chain HCAb [heavy-chain antibodies]), are derived from heavy-chain-only antibodies that circulate in sera camelids. Their exceptional physicochemical properties, possibility humanization, and unique antigen recognition properties make them excellent candidates for targeted delivery biologically active components, including immunotoxins. In our previous efforts, we have successfully generated the monovalent bivalent CD7...

10.2147/ijn.s127575 article EN cc-by-nc International Journal of Nanomedicine 2017-03-01

T cells expressing a chimeric antigen receptor (CAR) engineered to target CD19 can treat leukemia effectively but also increase the risk of complications such as cytokine release syndrome (CRS) and CAR cell related encephalopathy (CRES) driven by interleukin-6 (IL-6). Here, we investigated whether IL-6 knockdown in CART-19 reduce secretion from monocytes, which may adverse events.Supernatants cocultures regular B lymphoma were added monocytes vitro, levels monocyte supernatants measured 24 h...

10.1186/s40164-020-00166-2 article EN cc-by Experimental Hematology and Oncology 2020-06-08

Abstract CD19 chimeric antigen receptor (CAR) T-cell therapy has shown great success against B-cell acute lymphoblastic leukemia (B-ALL). Tandem and sequential CD19/CD22 dual-target CAR therapies have been developed to reduce the possibility of CD19-negative relapse; however, superior strategy is still uncertain. This study screened 219 patients with relapsed/refractory B-ALL who were enrolled in clinical trials either (NCT03919240) or (NCT03614858). The complete remission (CR) rates single...

10.1038/s41408-023-00819-5 article EN cc-by Blood Cancer Journal 2023-04-24

Abstract Deep penetration and downregulation of heat shock protein (HSP) expression in multimodal synergistic therapy are promising approaches for curing cancer clinical trials. However, free small‐molecule drugs most drug vehicles have a low delivery efficiency deep into the tumor owing to poor hypoxic conditions at site. In this study, objective is use reactive oxygen species (ROS)‐responsive supramolecular gels co‐loaded with photosensitizer Zn(II) phthalocyanine tetrasulfonic acid (ZnPCS...

10.1002/advs.202401214 article EN cc-by Advanced Science 2024-04-22

Acute myeloid leukemia (AML) is the most frequent in adults with a high mortality rate. Current diagnostic criteria and selections of therapeutic strategies are generally based on gene mutations cytogenetic abnormalities. Chemotherapy, targeted therapies, hematopoietic stem cell transplantation (HSCT) major for AML. Two dilemmas clinical management AML related to its poor prognosis. One inaccurate risk stratification at diagnosis, leading incorrect treatment selections. The other resistance...

10.1186/s40364-024-00600-1 article EN cc-by Biomarker Research 2024-06-10

Sterol regulatory element-binding proteins (SREBPs) are major transcription factors regulating the expression of genes involved in biosynthesis cholesterol, fatty acids, and triglycerides. We investigated effect specific SREBP suppressor andrographolide, a natural compound isolated from <i>Andrographis paniculata,</i> on regulation signaling by use Western blot, reporter gene assay, quantitative real-time polymerase chain reaction analysis. In addition, antiobesity effects andrographolide...

10.1124/jpet.114.217968 article EN Journal of Pharmacology and Experimental Therapeutics 2014-09-09

Extramedullary relapse (EMR) of acute leukemia (AL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a contributor to post-transplantation mortality and remains poorly understood, especially the different characteristics EMR in patients with myelogenous (AML) those lymphoblastic (ALL). To investigate incidence, risk factors, clinical outcomes for AML ALL, we performed retrospective analysis 362 AL who underwent allo-HSCT at First affiliated Hospital Soochow University...

10.1016/j.bbmt.2014.03.030 article EN cc-by-nc-nd Biology of Blood and Marrow Transplantation 2014-04-02

Gentiopicroside (GPS), one of iridoid glucoside representatives, is the most potential active component in Gentiana rigescens Franch. ex Hemsl and macrophylla Pall. These two herbs have been used to treat jaundice other hepatic billiary diseases traditional Chinese medicine for thousands years.This study aimed investigate protective effects mechanisms GPS on α-naphthylisothiocyanate (ANIT) induced cholestatic liver injury mice.Mice were treated with (130mg/kg, ig) 5 consecutive days. On...

10.1016/j.jep.2016.08.049 article EN cc-by-nc-nd Journal of Ethnopharmacology 2016-09-03

Abstract Cholestasis is a clinically significant symptom and widely associated with liver diseases, however, there are very few effective therapies for cholestasis. Danning tablet (DNT, Chinese patent medicine preparation) has been used to treat human gallbladder diseases more than 20 years in China. However, which ingredients of DNT contributed this beneficial effect their mechanistic underpinnings have largely unknown. In the present study, we discovered that not only demonstrated greater...

10.1038/srep33052 article EN cc-by Scientific Reports 2016-09-14

In plants, R2R3 MYB transcription factors (TFs) consist of one large gene family and are involved in the regulation many developmental processes various stresses. However, functions most TFs woody plants remain unknown. Here, PtrMYB94, an TF from Populus trichocarpa, is characterized to be drought responses abscisic acid (ABA) signaling. PtrMYB94 encodes a nuclear-localized TF. RT-PCR results showed that transcripts were relatively abundant leaves stems, induced rapidly response dehydration...

10.1093/treephys/tpz113 article EN Tree Physiology 2019-10-17

Background The use of T cells expressing chimeric antigen receptor (CAR T) engineered to target CD19 constitutes breakthrough treatment for relapsed or refractory B cell non-Hodgkin lymphoma (R/R B-NHL). Despite improved outcomes, high relapse rate remains a challenge overcome. Here, we report the clinical results and pharmacokinetics bispecific CD19/22 CAR in patients with R/R B-NHL. Methods We performed prospective, single-arm study analyzed safety efficacy investigated kinetic profiles...

10.3389/fonc.2021.664421 article EN cc-by Frontiers in Oncology 2021-05-25

Abstract The tumor burden (TB) is significantly related to the severity of cytokine release syndrome (CRS) caused by CAR-T cells, but its correlation with therapeutic efficacy has not been systematically studied. This study focused on effects TB level both safety and ssCART-19 as a treatment for r/r B-ALL. Taking 5% boundary, participants were divided into 2 groups, high low groups. Under this grouping strategy, impacts differential B-ALL TBs clinical (CR rate long-term survival) profiles...

10.1038/s41598-021-04296-3 article EN cc-by Scientific Reports 2022-01-10
Coming Soon ...